Indy100
A new trial drug has wiped out cancer in every single patient that took it.
The study was conducted with 18 rectal cancer patients at Memorial Sloan Kettering Cancer Center in Manhattan, New York, and had a 100 per cent success rate, as stated in a paper published in the New England Journal of Medicine.
In conversation with the New York Times, Dr. Luis A. Diaz Jr, the author of the paper, said the following: “I believe this is the first time this has happened in the history of cancer.”
The drug, which was sponsored by the drug company GlaxoSmithKline, is called dostarlimab.
It was administered to each patient every three weeks for a total of six months.
The participants in the study had colon cancer and were given alternative healing methods, such as chemotherapy or a difficult surgery that could potentially result in bowel or urinary dysfunction.
Some patients were required to use a colostomy bag due to treatment, the Times said.
Towards the end of the drug trial, the patients didn’t face the heartache of potentially damaging treatment when they showed no signs of a tumor after receiving an MRI, biopsy and rectal examination.
“There were a lot of happy tears,” Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center, told the outlet.
Alongside not needing any additional treatment to quell the disease, there were no instances of recurring cancers in the patients during their follow-up appointments from six to 25 months after the trial’s conclusion…
